159 related articles for article (PubMed ID: 37783120)
1. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.
Jing M; He X; Cai CZ; Ma QZ; Li K; Zhang BX; Yin Y; Shi MS; Wang YS
Biochem Biophys Res Commun; 2023 Nov; 681():218-224. PubMed ID: 37783120
[TBL] [Abstract][Full Text] [Related]
2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
3. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
4. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
6. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
7. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
9. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
12. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
[TBL] [Abstract][Full Text] [Related]
13. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
14. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
15. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
Giaccone G; He Y
Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
[TBL] [Abstract][Full Text] [Related]
16. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
Zeng J; Ding X; Ding J; Wang X
Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
[TBL] [Abstract][Full Text] [Related]
17. Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report.
Yang Z; Lin Y; Wang H
J Int Med Res; 2021 Aug; 49(8):3000605211035005. PubMed ID: 34396834
[TBL] [Abstract][Full Text] [Related]
18. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.
Chu X; Xu Y; Li Y; Zhou Y; Chu L; Yang X; Ni J; Li Y; Guo T; Zheng Z; Zheng Q; Yao Q; Li Y; Zhou X; Zhu Z
Lung Cancer; 2022 Jul; 169():22-30. PubMed ID: 35609408
[TBL] [Abstract][Full Text] [Related]
20. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
Wang X; Liang J; Li L; Pan Z; Wang L
Anticancer Drugs; 2023 Feb; 34(2):306-310. PubMed ID: 36206142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
